Related Experiment Videos
Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis
1Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospitals, State University of New York at Buffalo.
Pharmacoeconomics
|May 8, 1994
Summary
Cefepime demonstrates superior cost-effectiveness compared to ceftazidime in a retrospective analysis. Despite similar clinical success rates, cefepime offers better economic value for healthcare institutions.
Area of Science:
- Pharmacoeconomics
- Infectious Diseases
- Clinical Pharmacy
Background:
- Cefepime and ceftazidime are commonly used antibiotics.
- Evaluating the cost-effectiveness of antibiotics is crucial for healthcare resource allocation.
Purpose of the Study:
- To compare the cost-effectiveness of cefepime versus ceftazidime from an institutional perspective.
- To determine the economic advantage of cefepime in clinical practice.
Main Methods:
- Retrospective cost-effectiveness analysis of 1637 patients from randomized trials.
- Comparison of clinical success rates, adverse events, drug dosage, and treatment duration.
- Decision and sensitivity analyses incorporating drug price and hospital bed costs.
Main Results:
- Both cefepime and ceftazidime showed an 88% clinical success rate.
- Cefepime required significantly less drug per patient (17.6g vs 29.1g).
- Cefepime was consistently more cost-effective, even with similar acquisition prices per gram.
Conclusions:
- Cefepime presents a more favorable economic profile than ceftazidime.
- Ceftazidime would need to be substantially more effective to alter the cost-effectiveness decision.
- Cefepime is the preferred choice for cost-effective antibiotic therapy in this setting.